Status:
RECRUITING
Treatment and Prognosis of Patients With Chronic HBV Infection
Lead Sponsor:
Xiangya Hospital of Central South University
Conditions:
Hepatitis B Virus Infection
Eligibility:
All Genders
18-79 years
Brief Summary
Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's in...
Detailed Description
Patients with chronic HBV infection were recruited in the current study and divided in to peg-IFN-alpha alone group, NAs alone group and the combination therapy group. The serum HBV DNA level, HBV ser...
Eligibility Criteria
Inclusion
- patients with evidence of chronic HBV infection
Exclusion
- chronic liver injury mainly caused by other reasons, such as autoimmune diseases, alcohol, drugs and so on.
Key Trial Info
Start Date :
October 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 25 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05392387
Start Date
October 25 2021
End Date
October 25 2026
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Infectious Disease, Xiangya Hospital, Central South University
Changsha, Hunan, China, 410008